

# Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

Celina Ang<sup>1</sup>, Samuel J. Klempner<sup>2</sup>, Siraj M. Ali<sup>3</sup>, Russell Madison<sup>3</sup>, Jeffrey S. Ross<sup>3</sup>, Eric A. Severson<sup>3</sup>, David Fabrizio<sup>3</sup>, Aaron Goodman<sup>4</sup>, Razelle Kurzrock<sup>4</sup>, James Suh<sup>3</sup> and Sherri Z. Millis<sup>3</sup>

<sup>1</sup>Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA

<sup>2</sup>Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>3</sup>Foundation Medicine, Cambridge, MA, USA

<sup>4</sup>Department of Medicine, Division of Hematology and Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, USA

**Correspondence to:** Celina Ang, *email:* Celina.ang@mssm.edu

**Keywords:** immunotherapy; biomarkers; hepatocellular carcinoma; tumor mutation burden

**Received:** January 16, 2019

**Accepted:** May 20, 2019

**Published:** June 18, 2019

**Copyright:** Ang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

**The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive genomic profiling was performed to evaluate the frequency of genomic biomarkers of ICI response in 755 patients with advanced hepatocellular carcinoma (HCC). Median age was 62 years' old, 73% were male, 46% had extrahepatic disease, 107 had documented hepatitis C, 96 had hepatitis B and 4 patients were coinfecting. Median tumor mutation burden (TMB) was 4 mutations/Mb and only 6 tumors (0.8%) were TMB-high. Out of 542 cases assessed for microsatellite instability (MSI), one (0.2%) was MSI-high and TMB-high. Twenty-seven (4%) patients had *POLE/D* alterations. One patient had a pathogenic *POLE* R762W mutation but TMB was 4 mutations/Mb. Forty percent had DNA damage response gene alterations. In a small case series (N=17) exploring the relationship between biomarkers and ICI response, one patient (TMB 15 mutations/Mb, MSI-low) had a sustained complete response to nivolumab lasting > 2 years. Otherwise there were no significant genomic or TMB differences between responders, progressors, and those with stable disease. Overall, markers of genomic instability were infrequent in this cohort. Larger clinically annotated datasets are needed to explore genomic and non-genomic determinants of ICI response in HCC.**

## INTRODUCTION

Virally associated cancers like hepatocellular carcinoma (HCC) illustrate the disrupted balance between immune system attack and regulation [1]. The immune checkpoints PD-1 and CTLA-4 are activated in the presence of a chronic infection to suppress cytotoxic T cells and prevent immune-mediated host tissue damage. Cancer cells commandeer and manipulate these regulatory signals to escape immune surveillance, resulting in

unimpeded growth and metastasis. The concept of harnessing the immune system to attack cancer cells has been actualized with the development of immune checkpoint inhibitors (ICIs) which restore effector T cell function and cell mediated cytotoxicity. PD-1 inhibitors have shown activity across multiple solid and hematologic malignancies including HCC. Based on the results of the phase I/II CheckMate 040 and phase II KEYNOTE-224 trials [2, 3], nivolumab and pembrolizumab have been FDA approved for HCC after progression on sorafenib.

Additional trials expanding the use of ICIs in HCC in earlier treatment contexts are underway, with the results of the phase III CheckMate 459 trial of sorafenib vs nivolumab in first-line eagerly anticipated.

Responses to ICIs occur in a limited subset of patients across most cancer types including HCC [4]. An unmet need exists to develop predictive biomarkers to identify individuals most likely to respond to immunotherapies. PD-1 ligand (i.e. PD-L1) expression is an FDA approved companion biomarker used to select patients with esophagogastric adenocarcinoma or non-small cell lung cancer suitable for treatment with PD-1 inhibitors. Mismatch repair protein (MMR) deficiency or microsatellite instability (MSI) is also an FDA approved indication for the use of PD-1 inhibitors in advanced solid tumors given the strikingly higher response rates observed in MMR deficient/MSI-high compared to MMR proficient or MSI-low tumors [5]. Other emerging biomarkers include tumor mutation burden (TMB), alterations in DNA damage response (DDR) genes and DNA polymerases epsilon and delta (*POLE* and *POLD*), among others.

Owing to historically lower biopsy rates and poor outcomes, few studies have examined the landscape of putative immunotherapy biomarkers in advanced HCC. In this study, we survey the genomic landscape of 755 HCC specimens to identify patterns and associations with current as well as emerging biomarkers of response to PD-1 inhibitors. We also include a case series of patients with advanced HCC who received PD-1 inhibitors and evaluate their genomic profiles in the context of their responses to these agents.

## RESULTS

### Patient characteristics

The median age of diagnosis was 62 years old (range 19-91 years). Female and male patients were 27% and 73% percent, respectively. Hepatitis B (HBV) infection was determined by chart review (96 noted/suggested HBV+), of which 84 were also HBV+ by sequencing. Chart review identified 111 patients with hepatitis C (HCV, 4 co-infected with HBV). Seven patients had nonalcoholic steatohepatitis (NASH), 1 had a history of alcoholic liver disease, and 54 had cirrhosis of undocumented etiology. Nearly half (47%) had documented metastatic disease, with the most common sites of metastases being lung (8%), bone (6%), abdominopelvic soft tissue (6%), lymph nodes (4%) and adrenal gland (2%). Patient characteristics are summarized in Table 1.

### Mutational landscape of HCC

Known or likely pathogenic mutations were identified in 751 cases; the other 4 cases only had variants of unknown significance (VUS). The most commonly altered genes were *TERT* (44%), *TP53* (35%), *CTNNB1*

(31%), *ARID1A* (12%), and *MYC* (12%). All *MYC* alterations were amplifications. Mutations in *CDKN2A*, *RBI*, *ARID2*, *MCL1*, and *PTEN* occurred in 5-8% of specimens. Other alterations found at low rates that might be relevant for targeted therapies included *NTRK1* (2%), several PI3 kinase pathway genes (*TSC2*, *AKT3*, *STK11*), and *MET* (2-4%). No appreciable differences between the mutational profiles of primary HCCs and metastatic lesions were noted (data not shown). All alterations with a frequency >5% are shown in Figure 1.

### Tumor mutation burden (TMB), microsatellite status and PD-L1 expression

The median TMB for the entire cohort was 4 mutations/Mb, with 95% of cases having a TMB of < 10 mutations/Mb. Gender, HBV or HCV status, age and the proportion of primary vs metastatic tumors did not differ significantly amongst TMB subgroups (Table 2). Microsatellite status was determined in 542 specimens; only one was both MSI-high and TMB high (21 mutations/Mb). This specimen belonged to an 82 years' old Caucasian male with unknown risk factors or cirrhosis status. Three (50%) tumors were MSI-low in the TMB-high group, 128 (68%) in the TMB intermediate and 411 (73%) in the TMB-low group ( $p > 0.05$ ). Microsatellite status was ambiguous (ie. not MSI-low but below the MSI-high cutoff) in 4 specimens and not evaluable in 209 specimens.

PD-L1 expression levels were only available for 65 patients: 32 had "low positive", 3 had "high positive" scores, and 29 were PD-L1 negative. PD-L1 positivity was not associated with high TMB; the 3 patients with high positive PD-L1 were TMB low (2-5 mutations/Mb). Gene alteration frequencies in PD-L1 positive tumors are shown in Figure 1.

Differences in mutation profile amongst TMB subgroups were analyzed. Though TMB-high HCCs demonstrated some genetic differences compared to TMB-intermediate and low HCCs, their numbers were too small ( $N=6$ ) to be conclusive. No significant differences emerged between TMB low and intermediate HCCs (Figure 2).

Since 90% of specimens had a TMB of <10 mutations/Mb, we explored potential genetic differences using modified TMB cutoffs: TMB  $\leq 4$  mutations/Mb ( $N = 476$ ), 5-9 mutations/Mb ( $N = 227$ ),  $\geq 10$  mutations/Mb ( $N = 52$ ). The pattern and frequency of alterations associated with the new subgroups generally mirrored those observed with the original subgroups. Gene alterations that significantly differed between at least 2 of the new TMB subgroups are shown (Figure 3).

### POLE and D mutations

Alterations in the proofreading domains of *POLE* and *POLD* were detected in 27 of 755 specimens (4%):


**Table 1: Characteristics of study population and biomarker subgroups**

Patient characteristics	Biomarker subgroups			
	Total N = 755	PD-L1+ N = 35	POLE/D N = 27	DDR N = 306
Median age (range)	62 (19-91)	65	67	62
% Female:male	27:73	29:71	33:67	27:73
Known etiology (N = 269)				
Hepatitis B	96	2	2	37
Hepatitis C	111*	9	7	42
NASH	7		1	4
Alcohol	1			
Cirrhosis etiology unknown	54	3	2	12
Known site of tissue tested		13 (37%)	15 (55%)	144 (47%)
Liver	513 (68%)	5	8	51
Lymph nodes	30 (4%)	1		14
Lung	60 (8%)	2	3	28
Bone	45 (6%)	2	2	21
Abdominopelvic soft tissue	45 (6%)	2	1	18
Adrenal gland	15 (2%)			4
Other	47 (6%)	1 gallbladder	1 ovary	4 brain, 1 ovary, 1 kidney, 1 colon, 1 pancreas

\*4 coinfecting with Hepatitis B.

18 male and 9 female patients. A Caucasian male, 64 years' old with cirrhosis, TMB 4 mutations/Mb and MSI-low had a pathogenic *POLE R762W* mutation. The other 26 patients had *POLE/D* VUS. Median TMB of all patients with *POLE/D* variants was 5 mutations/Mb


with no statistically significant difference in *POLE/D* mutation frequency by etiology: 1/7 (14%) in patients with NASH, 2/96(2%) in patients with HBV including 4 coinfecting with HCV and 6/107 (6%) in patients with HCV only.




**Figure 1: Mutational landscape of HCC across study cohort and biomarker subgroups.**

**Table 2: Tumor mutation burden (TMB) distribution by etiology**

	TMB high	TMB intermediate	TMB low	All
<b>N (%)</b>	6 (1%)	188 (25%)	561 (74%)	755
<b>% Male:Female</b>	67:33	75:25	72:28	73:27
<b>Median age</b>	58 years	63 years	61 years	62 years
<b>Specimen site</b>				
Primary liver/not noted	2 (33%)	94 (50%)	252 (45%)	348
Metastasis	4 (67%)	94 (50%)	309 (55%)	407
<b>Liver disease etiology</b>				
HCV (no HBV)	0	27 (25%)	80 (75%)	107
HBV (± HCV)	0	31 (32%)	65 (68%)	96
NASH	0	1(14%)	6 (86%)	7



**Figure 2: Differences in gene alteration frequencies by TMB level.**



**Figure 3: Differences in gene alteration frequencies using modified TMB cutoffs (all genes shown have statistically significant differences between 2 or 3 groups).**

## DNA damage response (DDR) genes

Genomic analysis included 31 genes involved in various DNA repair pathways such as *POLE/D*, *BRCA 1/2*, and *ATM* (Supplementary Table 1). Forty percent ( $N = 306$ ) of 755 specimens contained DDR gene alterations including both pathogenic variants and VUS: 240 had one alteration, 47 had 2 alterations, 17 had 3 alterations, and 1 patient each had 4 and 5 alterations. Non DDR-altered HCCs had a significantly higher frequency of mutations in the *MYC* oncogene (14% vs. 9%,  $P = 0.05$ ) and *KEAPI*, a regulator of oxidative stress and inflammation (4% vs. 1%,  $P = 0.02$ ) [6]. DDR-altered tumors had non-significantly higher frequencies of mutations in *SPTA1* which encodes a molecular scaffold protein, cell cycle and intracellular signaling regulators *CDKN1B* and *IRS2* and the transcriptional regulator gene *NCOR1* (all 3% vs 1% in non DDR-altered tumors). TMB was not significantly different between DDR-altered and unaltered tumors. Furthermore, there were no significant differences in mutation profile or TMB levels between homologous recombination repair and DNA MMR pathways. Loss of heterozygosity (LOH) was evaluated as a possible mitigating factor, but fewer than 0.5% of patients exhibited LOH and no pattern with respect to any of the other parameters was identified (data not shown).

Gene alteration frequencies in tumors with *POLE/D* and DDR alterations are shown in Figure 1.

## Case series

Clinical data were available on 17 patients with advanced HCC who received a PD-1 inhibitor (Supplementary Table 2). Twelve patients were male and 10 were >65 years' old. Four patients were African-American, 6 were Asian, 3 were Caucasian and 4 were Hispanic. Seven patients had an objective response including one complete response, 6 had disease progression, 3 patients had stable disease and one patient discontinued treatment due to toxicity before response could be assessed. Eight patients were TMB-intermediate (6-15 mutations/Mb) and 9 were TMB-low (1-5 mutations/Mb). Sixteen cases were evaluable for microsatellite status; all were MSI-low.

The patient who had a durable (>2 year) complete response had a history of HCV and the highest TMB of all patients in the series (15 mutations/Mb). Overall, TMB levels did not segregate by response; 3 TMB-low patients responded to nivolumab, and 2 with TMB-high tumors had primary progression. One patient (#6) with TMB-intermediate disease received one dose of nivolumab and subsequently developed sepsis secondary to a hepatic abscess. Nivolumab was discontinued and the patient enrolled in hospice but was discharged 4 months later due to a sustained improvement in his clinical condition. Repeat imaging indicated that he had, in fact, responded to nivolumab, and that the abscess might have developed in the

context of tumor necrosis. Nivolumab was resumed for one dose but soon after he developed rapid disease progression and died one month later. Nine patients had DDR alterations: 6 patients who had a partial response or stable disease each had 1-2 alterations, 2 patients each with 2 variants had disease progression, and one patient with 4 variants received a single dose of nivolumab but was hospitalized for hepatic decompensation and discontinued treatment before response assessment. No patients had *POLE/D* alterations.

## DISCUSSION

Immune checkpoint inhibitors have revolutionized oncology treatment paradigms, but the high cost and potential for serious, albeit rare, adverse events with these agents demand judicious patient selection. Immunotherapy biomarker development has therefore become a research priority. Although PD-L1 expression is an FDA approved biomarker, its shortcomings including assay heterogeneity, variations in interpretation, and limited sensitivity for detecting responders [7, 8] has shifted attention to the concept of genomic instability as a predictor of susceptibility to PD-1 inhibitors.

The study population characteristics were reflective of the typical HCC patient profile with respect to gender ratio, age and sites of metastases. As clinical information was not available for most patients, risk factors were ascribed in only ~25% of cases, most of whom had viral hepatitis. The frequency and spectrum of genetic alterations in this cohort were consistent with prior series and expand on the genes interrogated more comprehensively [9–11].

Markers of genomic instability were generally infrequent in this cohort. Only one out of 542 evaluable specimens was MSI-high. In a recent series of 122 HCCs associated with a variety of etiologies and assessed using the gold standard pentaplex PCR technique, no tumors were MSI-high, but 26% exhibited lower levels of MSI [12]. Low level MSI tended to be more frequent in patients with cirrhosis, possibly reflecting genomic instability induced by chronic inflammation. In this series, 4 patients (0.7%) were microsatellite ambiguous (neither MSI-low nor MSI-high).

High nonsynonymous TMB is hypothesized to generate increased neoantigen expression by cancer cells [13], marking them as targets for an immune system activated by immune checkpoint inhibition. While increasing TMB correlates with higher response rates to PD-1 inhibitors [14–17], only 55% of the differences observed across tumor types are attributable to TMB [15], indicating that other factors may influence response to these agents [8]. Studies in metastatic melanoma and non-small cell lung cancer have also shown that TMB values in responders and nonresponders frequently overlap [14, 16]. Indeed, within our case series, TMB levels ranged from 3–15 mutations/Mb in patients who responded or had



stable disease, and from 4–9 mutations/Mb among those who progressed.

Although the availability of targeted next generation sequencing cancer gene panels has made TMB assessment more accessible and demonstrates comparable accuracy to whole exome sequencing [16, 18, 19], the application of TMB to clinical practice remains challenging. Currently no standardized gene platform exists to calculate TMB, definitions vary across studies, and tumor heterogeneity may result in TMB estimates that do not reflect the global TMB landscape within a tumor or across the total disease burden of a patient [20]. Furthermore, TMB ranges vary across tumor types [18], suggesting that disease specific TMB definitions should be explored. One might also speculate as to whether HCC TMB differs by type and number of risk factors (ie. HCV infection only vs HCV and alcohol). In this series, no discernable difference in TMB between HCV and HBV infected patients appeared.

The genetic profile of a tumor may also help to distinguish responders from nonresponders. In a study of pembrolizumab in non-small lung cancer, a “smoking signature” characteristic of tobacco-induced mutagenesis correlated with efficacy [21]. In this case series, there were no emergent genetic signals distinguishing responders from nonresponders due to the small number of patients.

*POLE/D* mutations appear to define a subset of cancers with an ultra-mutated phenotype that are often MSI-low and have been linked with durable responses to PD-1 inhibition in multiple tumor types [22, 23]. Within our study cohort, only one patient had a pathogenic *POLE* R762W mutation previously identified in colorectal cancer affecting the catalytic domain of the enzyme [24]. Notably, this patient had a TMB of only 4 mutations/Mb. The remaining patients evaluable for *POLE/D* alterations had VUS which, based on the low median TMB for the entire group, suggests that these variants were not associated with clinically meaningful changes in enzyme function.

Recently, DDR alterations have also been associated with an increased TMB, tumor lymphocytic infiltration and response to PD-1 inhibition [25]. In a retrospective series of metastatic urothelial cancers, the presence of DDR alterations, especially known pathogenic alterations, was independently associated with improved clinical outcomes on PD-1/PD-L1 inhibitors [25]. DDR alterations were prevalent in this cohort of HCCs and in our case series, both responders and nonresponders had  $\geq 1$  DDR alteration.

The process of biomarker discovery for immunotherapeutic agents is rapidly evolving. It is increasingly recognized that complex interactions between genetic, microenvironmental and systemic factors determine response or lack of response to these agents. Existing biomarkers appear to identify small, partially overlapping and/or complementary patient subgroups that, collectively, may cast a more inclusive net to identify treatment candidates. It is plausible to conceive of an

immunotherapy response prediction matrix consisting of TMB, genomic profile, cell surface protein expression and other emerging blood, stromal and even stool-based markers [26, 27] to facilitate patient selection in the future.

The main weakness of this study is the lack of clinical outcomes information for most patients precluding a more in-depth analysis of the relationships between specific biomarkers and response to PD-1 inhibition. Tumor specimens were heterogeneous with respect to site of origin and timing of procurement. The extent to which tumor genomic profiles were modified by prior treatments cannot be accounted for given the lack of clinical data. However, the consistency of our genomic profiling data with other studies [9–11] is reassuring.

In conclusion, this is the first study, to our knowledge, to evaluate the pattern and frequency of current and emerging biomarkers of response to PD-1 inhibitors in HCC. Gene alterations linked with hypermutability are infrequent in advanced HCC, and the apparent absence of an association between TMB and response to PD-1 inhibition suggests that future biomarker development in this context may need to look beyond markers of genomic instability. A follow-up study with clinical outcomes data is warranted to further elucidate determinants of response to PD-1 inhibitors in this disease.

## MATERIALS AND METHODS

Comprehensive genomic profiling (CGP) of 315 cancer-related genes was performed on 755 consecutive cases of hepatocellular carcinoma (2012-17) using a validated hybrid-capture, adaptor ligation based NGS assay (FoundationOne<sup>®</sup>) (Foundation Medicine, Cambridge, MA, USA; CLIA certified, CAP-accredited, NY State-approved laboratory). Pathologic diagnosis of each case was confirmed on routine hematoxylin and eosin-stained slides. A 20% minimum tumor nuclei content was required for DNA extraction, and genomic alterations (GA: point mutations, indels, copy number changes and rearrangements) were recorded (median coverage depth of 743x). Sequence analysis included hepatitis B (HBV) viral sequence reference genome alignment. Pathology reports were reviewed for documentation of HBV or hepatitis C (HCV). TMB was calculated from up to 1.1 megabase (Mb) of cancer genome as the number of somatic, coding point mutations and indels per Mb (low:  $<6$ ; intermediate: 6-19; high:  $\geq 20$  mutations/Mb). Microsatellite status was determined by a novel algorithm analyzing length variability of 114 specific homopolymer repeat loci and was evaluable in 542 of the 755 patients' tissues. PD-L1 immunostaining of 5 micron thick FFPE tissue sections was performed on the Dako Autostainer Link 48 platform and an automated staining protocol validated for the monoclonal mouse anti-human PD-L1 antibody, clone 22C3 pharmDx assay. Positive staining was defined as complete circumferential or partial cell membrane staining

of viable tumor cells. Scoring was recorded as percentage of PD-L1-positive tumor cells of the total tumor cells evaluated (TPS). The specimen was considered to have PD-L1 expression if TPS  $\geq$ 1% and high PD-L1 expression if TPS  $\geq$ 50% [28]. Only 65 of 755 patients had PD-L1 testing performed or documented. Approval for this study, including a waiver of informed consent and HIPAA waiver of authorization, was obtained from the Western Institutional Review Board (Protocol 20152817).

### Author contributions

CA, SZM and JS oversaw the study design. CA and SQ were responsible for data analysis and manuscript writing. All authors reviewed and approved the manuscript.

### ACKNOWLEDGMENTS

Some of the data in this manuscript were presented at the 2017 ESMO Asia meeting.

### CONFLICTS OF INTEREST

SMA, JSR, EAS, DF, JS, RM and SZM are employees of Foundation Medicine.

### REFERENCES

1. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2015; 12:681–700. <https://doi.org/10.1038/nrgastro.2015.173>. [PubMed]
2. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH 3rd, Meyer T, Kang YK, Yeo W, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet*. 2017; 389:2492–502. [https://doi.org/10.1016/S0140-6736\(17\)31046-2](https://doi.org/10.1016/S0140-6736(17)31046-2). [PubMed]
3. Zhu AX, Finn RS, Edeline J, Cattani S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, et al, and KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*. 2018; 19:940–52. [https://doi.org/10.1016/S1470-2045\(18\)30351-6](https://doi.org/10.1016/S1470-2045(18)30351-6). [PubMed]
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012; 366:2443–54. <https://doi.org/10.1056/NEJMoa1200690>. [PubMed]
5. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, et al. PD-1 blockade in tumors with mismatch repair deficiency. *N Engl J Med*. 2015; 372:2509–20. <https://doi.org/10.1056/NEJMoa1500596>. [PubMed]
6. Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. *Histopathology*. 2012; 60:943–52. <https://doi.org/10.1111/j.1365-2559.2012.04178.x>. [PubMed]
7. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clin Cancer Res*. 2014; 20:5064–74. <https://doi.org/10.1158/1078-0432.CCR-13-3271>. [PubMed]
8. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer*. 2016; 16:275–87. <https://doi.org/10.1038/nrc.2016.36>. [PubMed]
9. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. *Gastroenterology*. 2015; 149:1226–1239.e4. <https://doi.org/10.1053/j.gastro.2015.05.061>. [PubMed]
10. Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. *J Surg Oncol*. 2016; 113:55–61. <https://doi.org/10.1002/jso.24086>. [PubMed]
11. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. *J Hepatol*. 2016; 65:1031–42. <https://doi.org/10.1016/j.jhep.2016.05.035>. [PubMed]
12. Goumard C, Desbois-Mouthon C, Wendum D, Calmel C, Merabtene F, Scatton O, Praz F. Low levels of microsatellite instability at simple repeated sequences commonly occur in human hepatocellular carcinoma. *Cancer Genomics Proteomics*. 2017; 14:329–39. <https://doi.org/10.21873/cgp.20043>. [PubMed]
13. Nebot-Bral L, Brandao D, Verlingue L, Rouleau E, Caron O, Despras E, El-Dakdouki Y, Champiat S, Aoufouchi S, Leary A, Marabelle A, Malka D, Chaput N, Kannouche PL. Hypermutated tumours in the era of immunotherapy: the paradigm of personalised medicine. *Eur J Cancer*. 2017; 84:290–303. <https://doi.org/10.1016/j.ejca.2017.07.026>. [PubMed]
14. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med*. 2014; 371:2189–99. <https://doi.org/10.1056/NEJMoa1406498>. [PubMed]

15. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. *N Engl J Med.* 2017; 377:2500–01. <https://doi.org/10.1056/NEJMc1713444>. [PubMed]
16. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, et al. Molecular determinants of response to anti-programmed death (PD)-1 and anti-PD-Ligand 1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. *J Clin Oncol.* 2018; 36:633–41. <https://doi.org/10.1200/JCO.2017.75.3384>. [PubMed]
17. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther.* 2017; 16:2598–608. <https://doi.org/10.1158/1535-7163.MCT-17-0386>. [PubMed]
18. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med.* 2017; 9:34. <https://doi.org/10.1186/s13073-017-0424-2>. [PubMed]
19. Campesato LF, Barroso-Sousa R, Jimenez L, Correa BR, Sabbaga J, Hoff PM, Reis LF, Galante PA, Camargo AA. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. *Oncotarget.* 2015; 6:34221–27. <https://doi.org/10.18632/oncotarget.5950>. [PubMed]
20. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann Oncol.* 2019; 30:44–56. <https://doi.org/10.1093/annonc/mdy495>. [PubMed]
21. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science.* 2015; 348:124–28. <https://doi.org/10.1126/science.aaa1348>. [PubMed]
22. Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. *J Natl Compr Canc Netw.* 2017; 15:142–47. <https://doi.org/10.6004/jnccn.2017.0016>. [PubMed]
23. Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, Church DN. A panoply of errors: polymerase proofreading domain mutations in cancer. *Nat Rev Cancer.* 2016; 16:71–81. <https://doi.org/10.1038/nrc.2015.12>. [PubMed]
24. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, et al, and CORGI Consortium, and WGS500 Consortium. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet.* 2013; 45:136–44. <https://doi.org/10.1038/ng.2503>. [PubMed]
25. Teo MY, Seier K, Ostrovskaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. *J Clin Oncol.* 2018; 36:1685–94. <https://doi.org/10.1200/JCO.2017.75.7740>. [PubMed]
26. Friedman CF, Postow MA. Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition. *Curr Oncol Rep.* 2016; 18:21. <https://doi.org/10.1007/s11912-016-0509-x>. [PubMed]
27. Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillyère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science.* 2018; 359:91–97. <https://doi.org/10.1126/science.aan3706>. [PubMed]
28. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. *Appl Immunohistochem Mol Morphol.* 2016; 24:392–97. <https://doi.org/10.1097/PAI.0000000000000408>. [PubMed]